First Ever Drug from Genetically Modified Animals Goes to Market
Milk product will be used for the prevention of blood clots in patients with a rare disease.
Pasadena, CA, May 08, 2009 --(PR.com)-- BiomedReports.Com is presenting a special report, complete with video, demonstrating the first transgenically produced drug available in the U.S.
The drug is the first ever biological product produced by a genetically engineered animal - a goat.
Derived from the milk of goats, ATryn is a therapeutic protein. The goats were genetically engineered by GTC Biotherapeutics, Inc. after introducing a segment of DNA into their genes (DNA or rDNA construct) with instructions for the goat to produce human antithrombin in its milk. Antithrombin occurs naturally in healthy humans - it helps keep blood from clotting in blood vessels.
Lundbeck, a wholly owned subsidiary of H. Lundbeck A/S in Denmark, will pay the $1 million for GTC’s first supply of ATryn.
The full special report on the first human drug of it's kind appears at the link below:
http://biomedreports.com/articles/most-popular/910-first-ever-drug-from-a-genetically-modified-animal-goes-to-market.html
About BiomedReports.Com
BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into various new healthcare stock indexes.
The full report can be seen on demand at BiomedReports.com
About BiomedReports.Com
BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content – including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into various new healthcare stock indexes.
For more biomedical sector and investment news, go to BiomedReports.Com
Disclosure: No positions.
###
The drug is the first ever biological product produced by a genetically engineered animal - a goat.
Derived from the milk of goats, ATryn is a therapeutic protein. The goats were genetically engineered by GTC Biotherapeutics, Inc. after introducing a segment of DNA into their genes (DNA or rDNA construct) with instructions for the goat to produce human antithrombin in its milk. Antithrombin occurs naturally in healthy humans - it helps keep blood from clotting in blood vessels.
Lundbeck, a wholly owned subsidiary of H. Lundbeck A/S in Denmark, will pay the $1 million for GTC’s first supply of ATryn.
The full special report on the first human drug of it's kind appears at the link below:
http://biomedreports.com/articles/most-popular/910-first-ever-drug-from-a-genetically-modified-animal-goes-to-market.html
About BiomedReports.Com
BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into various new healthcare stock indexes.
The full report can be seen on demand at BiomedReports.com
About BiomedReports.Com
BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content – including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into various new healthcare stock indexes.
For more biomedical sector and investment news, go to BiomedReports.Com
Disclosure: No positions.
###
Contact
BiomedReports.com
Mike Havrilla
323-472-4480
www.biomedreports.com
Mike Havrilla
323-472-4480
www.biomedreports.com
Contact
Categories